Welcome to our dedicated page for Sinovac Biotech news (Ticker: SVA), a resource for investors and traders seeking the latest updates and insights on Sinovac Biotech stock.
Sinovac Biotech Ltd. (NASDAQ: SVA) is a China-based global biopharmaceutical company focused on the R&D, manufacturing, and commercialization of vaccines that protect against human infectious diseases. The SVA news page on Stock Titan aggregates company press releases, regulatory updates, and third-party coverage so readers can follow developments affecting this vaccine manufacturer.
News about Sinovac frequently centers on its vaccine portfolio and public health role, including products such as CoronaVac® for COVID‑19, Healive® for hepatitis A, Inlive® for EV71-related Hand-Foot-Mouth disease (HFMD), and vaccines for varicella, influenza, poliomyelitis, and pneumococcal disease. Articles also highlight WHO prequalification of several Sinovac vaccines and the company’s history of developing vaccines during outbreaks of SARS, H5N1, H1N1, and COVID‑19.
Investors and observers can also use this page to track corporate governance, legal, and listing-related news. Recent company communications describe litigation in Antigua over PIPE shares and shareholder voting, competing claims regarding board composition, and court orders governing Sinovac’s board and corporate actions. Updates on proxy contests, special shareholder meetings, and dividend decisions are commonly reported through company press releases and furnished to the SEC on Form 6‑K.
Another key news theme is financial reporting and auditor engagement. Sinovac has issued announcements about the resignation and appointment of independent auditors, the engagement of UHY LLP and later Zhonghua Certified Public Accountants LLP, and its efforts to complete multi-year audits and file outstanding Form 20‑Fs and Form 6‑Ks. Related Nasdaq notices regarding late filings and a delisting determination letter are also disclosed in news items.
By reviewing the SVA news feed, readers can monitor Sinovac’s vaccine-related milestones, regulatory and legal developments, dividend actions, and progress toward meeting SEC and Nasdaq requirements. This page can be revisited regularly for the latest company-issued statements and market-relevant updates.
Sinovac (Nasdaq: SVA) said the Nasdaq Hearings Panel granted its request to continue listing, conditional on remediation of filing delinquencies and completion of its financial audit.
The company must demonstrate compliance by May 11, 2026 by filing its Form 20-F for year ended Dec 31, 2024 and an interim Form 6-K containing an end-of-second-quarter 2025 balance sheet and income statement. Sinovac disclosed it engaged Zhonghua Certified Public Accountants LLP as its independent registered public accounting firm (disclosed Jan 4, 2026) and is working with Zhonghua to complete the required audit and regain compliance.
Sinovac (NASDAQ: SVA) said the Antigua High Court updated an interlocutory order naming ten directors to comprise the Company board until the trial listed in late April/early May 2026, and noted that Rui-Ping Xiao resigned for personal reasons. The Company also announced the Audit Committee approved engagement of Zhonghua as independent auditor effective December 31, 2025. Zhonghua is registered in China and with the PCAOB, and its engagement supersedes UHY LLP.
The company said seven of nine board members are independent and all Audit, Compensation and Nominating & Corporate Governance committee members are independent.
Sinovac (NASDAQ: SVA) received a Nasdaq notification dated January 2, 2026 saying the company was not in compliance with Nasdaq Listing Rule 5250(c)(2) after failing to timely file a Form 6-K containing an interim balance sheet and income statement for the second quarter of 2025.
As previously disclosed, Nasdaq issued a delisting determination in November 2025; the company requested a hearing on November 19, 2025. Nasdaq informed Sinovac the Nasdaq Hearings Panel will consider the late‑filing notice at a hearing scheduled for January 8, 2026, where Sinovac has been invited to present its plan and views aimed at maintaining its Nasdaq listing.
Sinovac (NASDAQ: SVA) announced that the Antigua High Court made an interim order appointing eight directors as the Company's Board until the trial of a disputed Special Shareholders Meeting, now listed for late April/early May 2026. The court hearing occurred on 27 October 2025, and the dispute concerns the outcome of the 8 July 2025 Special Shareholders Meeting.
A Board meeting on 17 December 2025 reaffirmed commitment to shareholder value, to complete the audit with the Audit Committee, to work with management and advisors, to seek restoration of NASDAQ trading, and to pursue negotiated resolutions among parties.
Sinovac (Nasdaq: SVA) received a delisting determination from Nasdaq on November 12, 2025 for non-compliance with Nasdaq Listing Rule 5250(c)(1) after failing to timely file its Form 20-F for the year ended December 31, 2024 by the extension deadline of November 11, 2025.
The company previously disclosed Grant Thornton Zhitong's resignation on April 15, 2025, engaged UHY LLP as its new independent registered public accounting firm on October 24, 2025, and intends to request a hearing with the Nasdaq Hearing Panel on or before November 19, 2025 to appeal the Staff Determination and seek stays of any suspension or delisting while UHY completes the audit.
Summary not available.
SINOVAC (NASDAQ: SVA) announced that its Audit Committee approved the engagement of UHY LLP as the company’s independent auditor, effective October 24, 2025. UHY will audit SINOVAC’s financial statements for the years ended Dec 31, 2021–2025, perform internal control audits as of Dec 31, 2024 and 2025, and conduct interim reviews for the six-month periods ended June 30, 2024 and 2025.
The company said it plans to file Form 20-Fs and Form 6-Ks as soon as practicable to meet SEC and NASDAQ compliance requirements, and described the appointment as a critical step toward improved transparency and the aim of resuming trading on NASDAQ Beijing.
SINOVAC Biotech (NASDAQ: SVA) has issued a statement regarding its July 8, 2025 Special Meeting of Shareholders, which was validly adjourned by Chairman Chiang Li due to pending litigation in Antigua concerning disputed PIPE shares. The company is addressing unauthorized actions by SAIF and the Dissenting Investor Group, who allegedly conducted an invalid meeting after the official adjournment.
The current Board, led by Dr. Chiang Li, maintains its authority and continues to execute key priorities, including: dividend distributions, a special cash dividend of $55.00 per share, working towards NASDAQ trading resumption, appointing a new auditor, and exploring a potential Hong Kong Stock Exchange listing.
The Special Meeting will be reconvened once the Antigua court makes a final decision on the validity of the PIPE shares issued to Advantech/Prime and Vivo Capital.
Sinovac Biotech (NASDAQ: SVA) announced the first meeting of its newly elected Board of Directors following the July 8, 2025 Special Meeting. The new board was elected with 33,248,861 votes (54.71%) of total votes. Mr. Andrew Y. Yan, Managing Partner of SAIF Partners, was elected as Chairman of the Board.
The Board outlined key priorities including exploring future dividend plans, appointing a new auditor to resume NASDAQ trading, resolving ongoing shareholder litigations, and restoring stable operations. The Board confirmed Mr. Yin Weidong will continue as Executive Director and CEO of the company.
SINOVAC Biotech (NASDAQ: SVA) strongly denounces recent claims made by SAIF and the Imposter Former Board regarding a Special Meeting of Shareholders. The company's Chairman Chiang Li validly adjourned the July 8, 2025 meeting pending litigation resolution in Antigua concerning 11.8 million disputed PIPE shares issued to the Dissenting Investor Group.
According to Georgeson, SINOVAC's proxy solicitor, the company's White Proxy Card received strong support from valid shareholders before the adjournment. The current Board maintains it is the only legitimate governing body and accuses SAIF of conducting unauthorized vote tallying and making illegal claims about reconvening the meeting.
The company is evaluating legal remedies against SAIF and the Imposter Former Board in both Antigua and the United States while working to implement the UK Privy Council's judgment regarding the PIPE shares validity.